Peficitinib improves bone fragility by recovering bone turnover imbalance in arthritic mice

Peficitinib, a pan-JAK inhibitor, is known to suppress the activation of fibroblast-like synoviocytes (FLSs) and thereby reduces joint inflammation associated with rheumatoid arthritis (RA). However, the effect on osteoporosis in RA remains to be elucidated. In this study, the effect of peficitinib...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Shingo Sugahara, Kaori Hanaoka, Takashi Emori, Nobuaki Takeshita, Yasutomo Fujii, Masaki Nakano, Takako Suzuki, Jun Takahashi, Yukio Nakamura
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2022-01-01
Edice:	Journal of Pharmacological Sciences
Témata:	Arthritis Osteoporosis Osteoclast/osteoblast biology Peficitinib Bone density
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S1347861321001018
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!